Last reviewed 2026-04-23 · How we verify

HS-20093

HS-20093 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.

HS-20093 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered solid tumors (Phase 3 development).

At a glance

Mechanism of action

HS-20093 targets FGFR kinase activity to inhibit downstream proliferation and survival pathways in tumors with FGFR alterations. By selectively blocking FGFR signaling, the drug aims to suppress tumor growth in cancers driven by FGFR mutations, amplifications, or fusions.

Approved indications

• FGFR-altered solid tumors (Phase 3 development)

Common side effects

• Hyperphosphatemia
• Diarrhea
• Fatigue
• Nausea

Key clinical trials

• A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (PHASE3)
• HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (PHASE1)
• A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases (EARLY_PHASE1)
• A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (PHASE2)
• Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors (PHASE1)
• Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer (PHASE1)
• Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer (PHASE1)
• HS-10502 Combination Treatment in Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.